Ghost Tree Capital
Latest statistics and disclosures from Ghost Tree Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ALNY, INSM, BHVN, MLTX, SLNO, and represent 25.77% of Ghost Tree Capital's stock portfolio.
- Added to shares of these 10 stocks: ASND (+$12M), CATX (+$9.2M), INSM (+$7.7M), ALNY (+$7.5M), BHVN (+$7.1M), RZLT (+$6.1M), CGON (+$5.8M), CRBP (+$5.3M), PCVX, SNDX.
- Started 11 new stock positions in ANNX, MGNX, ASND, JANX, PTCT, CATX, NUVB, WVE, RZLT, KRRO. PRQR.
- Reduced shares in these 10 stocks: , SRPT (-$11M), , AVTE (-$6.7M), TGTX (-$5.8M), AXSM, BPMC, CYTK, ACAD, GPCR.
- Sold out of its positions in AVTE, ALT, AQST, ATXS, COGT, Deciphera Pharmaceuticals, EYPT, GERN, IsoRay, KALV. LRMR, MDGL, MRNS, NTRA, PTGX, XBI, GPCR, RARE, QURE.
- Ghost Tree Capital was a net seller of stock by $-16M.
- Ghost Tree Capital has $319M in assets under management (AUM), dropping by -11.61%.
- Central Index Key (CIK): 0001595851
Tip: Access up to 7 years of quarterly data
Positions held by Ghost Tree Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Ghost Tree Capital
Ghost Tree Capital holds 60 positions in its portfolio as reported in the June 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals (ALNY) | 6.9 | $22M | +51% | 91k | 243.00 |
|
| Insmed Com Par $.01 (INSM) | 5.6 | $18M | +76% | 265k | 67.00 |
|
| Biohaven (BHVN) | 5.3 | $17M | +71% | 490k | 34.71 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 4.1 | $13M | 300k | 43.97 |
|
|
| Soleno Therapeutics (SLNO) | 3.8 | $12M | +50% | 300k | 40.80 |
|
| Axsome Therapeutics (AXSM) | 3.8 | $12M | -28% | 150k | 80.50 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 3.7 | $12M | NEW | 87k | 136.38 |
|
| Vaxcyte (PCVX) | 3.5 | $11M | +57% | 150k | 75.51 |
|
| Crinetics Pharmaceuticals In (CRNX) | 3.4 | $11M | +20% | 240k | 44.79 |
|
| Roivant Sciences SHS (ROIV) | 3.3 | $11M | -23% | 1.0M | 10.57 |
|
| Perspective Therapeutics Com New (CATX) | 2.9 | $9.2M | NEW | 925k | 9.97 |
|
| Tg Therapeutics (TGTX) | 2.8 | $8.9M | -39% | 500k | 17.79 |
|
| Sarepta Therapeutics (SRPT) | 2.7 | $8.7M | -56% | 55k | 158.00 |
|
| Cg Oncology (CGON) | 2.6 | $8.2M | +246% | 260k | 31.57 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 2.5 | $7.9M | +207% | 175k | 45.25 |
|
| Miragen Therapeutics (VRDN) | 2.4 | $7.6M | -5% | 588k | 13.01 |
|
| Syndax Pharmaceuticals (SNDX) | 2.3 | $7.2M | +133% | 350k | 20.53 |
|
| Immunovant (IMVT) | 2.1 | $6.9M | -5% | 260k | 26.40 |
|
| Tarsus Pharmaceuticals (TARS) | 2.0 | $6.4M | -21% | 235k | 27.18 |
|
| Phathom Pharmaceuticals (PHAT) | 1.9 | $6.2M | +23% | 600k | 10.30 |
|
| Rezolute Com New (RZLT) | 1.9 | $6.1M | NEW | 1.4M | 4.30 |
|
| Olema Pharmaceuticals (OLMA) | 1.9 | $6.0M | +175% | 550k | 10.82 |
|
| Spyre Therapeutics Com New (SYRE) | 1.8 | $5.9M | +150% | 250k | 23.51 |
|
| Apellis Pharmaceuticals (APLS) | 1.6 | $5.2M | +3% | 135k | 38.36 |
|
| Viking Therapeutics (VKTX) | 1.6 | $5.0M | -37% | 95k | 53.01 |
|
| Rhythm Pharmaceuticals (RYTM) | 1.5 | $4.8M | -6% | 117k | 41.06 |
|
| Blueprint Medicines (BPMC) | 1.4 | $4.3M | -45% | 40k | 107.78 |
|
| Savara (SVRA) | 1.3 | $4.2M | -34% | 1.1M | 4.03 |
|
| Tenaya Therapeutics (TNYA) | 1.3 | $4.2M | +74% | 1.4M | 3.10 |
|
| Replimune Group (REPL) | 1.3 | $4.1M | -30% | 450k | 9.00 |
|
| Engene Holdings (ENGN) | 1.2 | $4.0M | +110% | 420k | 9.43 |
|
| ACADIA Pharmaceuticals (ACAD) | 1.1 | $3.7M | -47% | 225k | 16.25 |
|
| Bridgebio Pharma (BBIO) | 1.1 | $3.5M | -20% | 140k | 25.33 |
|
| Korro Bio (KRRO) | 1.1 | $3.4M | NEW | 100k | 33.87 |
|
| Nuvation Bio Com Cl A (NUVB) | 1.1 | $3.4M | NEW | 1.2M | 2.92 |
|
| Helix Acquisition Corp Ii Cl A Ord Shs (HLXB) | 1.0 | $3.1M | 300k | 10.22 |
|
|
| Taysha Gene Therapies Com Shs (TSHA) | 0.9 | $2.8M | +31% | 1.3M | 2.24 |
|
| Cabaletta Bio (CABA) | 0.9 | $2.8M | 371k | 7.48 |
|
|
| Annexon (ANNX) | 0.8 | $2.6M | NEW | 525k | 4.90 |
|
| Neurogene (NGNE) | 0.8 | $2.5M | +180% | 70k | 36.39 |
|
| Janux Therapeutics (JANX) | 0.7 | $2.1M | NEW | 50k | 41.89 |
|
| Arvinas Ord (ARVN) | 0.6 | $2.0M | +87% | 75k | 26.62 |
|
| Regenxbio Inc equity us cm (RGNX) | 0.6 | $2.0M | +41% | 170k | 11.70 |
|
| Cytokinetics Com New (CYTK) | 0.6 | $1.8M | -65% | 33k | 54.18 |
|
| Elevation Oncology (ELEV) | 0.5 | $1.6M | +140% | 600k | 2.70 |
|
| Krystal Biotech (KRYS) | 0.5 | $1.6M | -39% | 8.5k | 183.64 |
|
| Proqr Thrapeutics N V Shs Euro (PRQR) | 0.5 | $1.5M | NEW | 900k | 1.66 |
|
| Atyr Pharma Com New (ATYR) | 0.4 | $1.2M | +33% | 800k | 1.56 |
|
| Wave Life Sciences SHS (WVE) | 0.3 | $998k | NEW | 200k | 4.99 |
|
| Rapt Therapeutics Call Option (RAPT) | 0.3 | $915k | 300k | 3.05 |
|
|
| Arrowhead Pharmaceuticals (ARWR) | 0.3 | $910k | 35k | 25.99 |
|
|
| Sagimet Biosciences Com Ser A (SGMT) | 0.2 | $770k | 225k | 3.42 |
|
|
| Intra Cellular Therapies (ITCI) | 0.2 | $685k | -80% | 10k | 68.49 |
|
| Macrogenics (MGNX) | 0.2 | $638k | NEW | 150k | 4.25 |
|
| Pmv Pharmaceuticals (PMVP) | 0.2 | $608k | -44% | 375k | 1.62 |
|
| Ptc Therapeutics I (PTCT) | 0.2 | $581k | NEW | 19k | 30.58 |
|
| Revance Therapeutics (RVNC) | 0.2 | $578k | -50% | 225k | 2.57 |
|
| Intellia Therapeutics (NTLA) | 0.2 | $560k | 25k | 22.38 |
|
|
| An2 Therapeutics (ANTX) | 0.1 | $472k | 219k | 2.15 |
|
|
| Cytomx Therapeutics (CTMX) | 0.1 | $366k | -50% | 300k | 1.22 |
|
Past Filings by Ghost Tree Capital
SEC 13F filings are viewable for Ghost Tree Capital going back to 2013
- Ghost Tree Capital 2024 Q2 filed Aug. 14, 2024
- Ghost Tree Capital 2024 Q1 filed May 15, 2024
- Ghost Tree Capital 2023 Q4 filed Feb. 14, 2024
- Ghost Tree Capital 2023 Q3 filed Nov. 14, 2023
- Ghost Tree Capital 2023 Q2 filed Aug. 14, 2023
- Ghost Tree Capital 2023 Q1 filed May 15, 2023
- Ghost Tree Capital 2022 Q4 filed Feb. 14, 2023
- Ghost Tree Capital 2022 Q3 filed Nov. 14, 2022
- Ghost Tree Capital 2022 Q2 filed Aug. 15, 2022
- Ghost Tree Capital 2022 Q1 filed May 16, 2022
- Ghost Tree Capital 2021 Q4 filed Feb. 16, 2022
- Ghost Tree Capital 2021 Q3 filed Nov. 15, 2021
- Ghost Tree Capital 2021 Q1 restated filed Aug. 11, 2021
- Ghost Tree Capital 2021 Q2 filed Aug. 11, 2021
- Ghost Tree Capital 2021 Q1 filed May 14, 2021
- Ghost Tree Capital 2020 Q4 restated filed Feb. 18, 2021